“This quarter marks a turning point in the evolution of MiNK. Our platform is demonstrating the power of iNKT cells to transform immune responses in both cancer and inflammatory diseases,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics (INKT). “With late-stage strategic discussions underway across oncology, immunology, and next-generation engineered cell therapies, MiNK is positioned to unlock the full value of our technology. These partnerships-alongside our clinical advances and expanded access to non-dilutive capital-will allow us to deliver off-the-shelf iNKT therapies to patients with urgency, focus, and scale.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- INKT Upcoming Earnings Report: What to Expect?
- MiNK Therapeutics Reports 2024 Progress and Financials
- MiNK Therapeutics’ Earnings Call Highlights Strategic Gains
- Buy Rating Affirmed for MiNK Therapeutics Amid Promising Clinical Developments and Strategic Expansion
- Promising Clinical Data and Strategic Initiatives Drive Buy Rating for MiNK Therapeutics
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue